CriticalAntiepileptics. Carboxamide derivatives×Selective irreversible MAO-B inhibitor
Updated · Methodology
Mechanism
Selegiline irreversibly inhibits monoamine oxidase (MAO), selectively type B at recommended doses. In the liver, CYP2B6 is the main enzyme that metabolises selegiline, with a possible contribution from CYP3A4 and CYP2A6 (selegiline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 5.1 and 5.2). The Spanish carbamazepine SmPC contraindicates carbamazepine with MAO inhibitors without explaining the mechanism (carbamazepine SmPC, AEMPS, sections 4.3 and 4.5). The US label bases the restriction on theoretical grounds (carbamazepine label, US Food and Drug Administration, FDA, Contraindications). Carbamazepine is a strong inducer of CYP3A4 and other liver enzymes (carbamazepine SmPC, AEMPS, section 4.4). Yet a study in the US label for transdermal selegiline found the opposite: after 14 days of carbamazepine 400 mg a day, a single 6 mg/24 h selegiline patch gave about twice the exposure to selegiline and its metabolites L-amphetamine and L-methamphetamine, with wide variation between people (transdermal selegiline FDA label, section 12.3). Such an increase may raise the risk of hypertensive crisis (transdermal selegiline FDA label, section 5.3), and the effect of CYP3A4 inducers on selegiline tablets has not been adequately studied (FDA label for selegiline tablets, section 7.7).
Symptoms
The documents do not describe how this combination presents with selegiline tablets. For transdermal selegiline, the US label links the combination with carbamazepine to a risk of hypertensive crisis (transdermal selegiline label, US Food and Drug Administration, FDA, sections 4 and 5.3). Such a crisis presents with an occipital headache that may spread to the forehead, palpitations, neck stiffness or soreness, nausea, vomiting, sweating (sometimes with fever and sometimes with cold, clammy skin), dilated pupils and sensitivity to light. The heart rate may be fast or slow, sometimes with constricting chest pain. Intracranial bleeding has been reported with the rise in blood pressure, and in some cases the crisis may be fatal (transdermal selegiline FDA label, section 5.3).
Management
The combination is contraindicated. The Spanish carbamazepine summary of product characteristics (SmPC) prohibits carbamazepine with monoamine oxidase (MAO) inhibitors and names the class without a list (carbamazepine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). According to its own SmPC, selegiline is an MAO type B inhibitor (selegiline SmPC, AEMPS, section 5.1). The US label for transdermal selegiline contraindicates carbamazepine by name and states that carbamazepine is contraindicated with MAO inhibitors, including selegiline (transdermal selegiline label, US Food and Drug Administration, FDA, sections 4 and 7.4). Other documents are milder. The US carbamazepine label does not recommend combining carbamazepine with MAO inhibitors, on theoretical grounds (FDA carbamazepine label, Contraindications). The US label for selegiline tablets advises caution with CYP3A4 inducers, including carbamazepine (FDA selegiline label, section 7.7), and the Spanish selegiline SmPC does not mention carbamazepine. Start carbamazepine no earlier than 2 weeks after stopping selegiline, or later if the clinical situation allows (carbamazepine SmPC, AEMPS, section 4.5; FDA carbamazepine label, Contraindications). The documents give no interval for switching from carbamazepine to selegiline tablets. Before transdermal selegiline, which is not authorised in Spain (AEMPS medicines register), the US label says to wait 4–5 half-lives of the drug or its active metabolite, about one week (transdermal selegiline FDA label, section 4). If a hypertensive crisis occurs in a patient using transdermal selegiline, stop selegiline and start lowering blood pressure immediately, treat fever with external cooling and monitor the patient closely until the symptoms stabilise (transdermal selegiline FDA label, section 5.3).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Carbamazepina (nº registro 39955), secciones 4.3, 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 39955, revisión 09/2026, secciones 4.3, 4.4 y 4.5
- FDA: Tegretol (carbamazepine) prescribing information (2026)– FDA label, DailyMed setid 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053, version 39, revised 08/2026, Contraindications and PRECAUTIONS: Drug Interactions
- AEMPS: Ficha técnica: Selegilina, Plurimen 5 mg (nº registro 58113) (2026)– AEMPS, CIMA, nº registro 58113 (Plurimen 5 mg comprimidos), revisión 03/2026, secciones 4.3, 4.4, 4.5 y 5.1
- FDA: Zelapar (selegiline hydrochloride) prescribing information (2021)– FDA label, Bausch Health US, LLC, DailyMed setid 380d7717-2a79-42f3-a712-efe5e7696ba0, revised 06/2021, sections 4, 5.1 and 7.1
- FDA: Emsam (selegiline transdermal system) prescribing information (2020)– FDA label, Viatris Specialty LLC, DailyMed setid b891bd9f-fdb8-4862-89c5-ecdd700398a3, revised 05/2020, section 4